25 XP   0   0   10

Aileron Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Aileron Therapeutics Inc together

PenkeI guess you are interested in Aileron Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aileron Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Aileron Therapeutics Inc

I send you an email if I find something interesting about Aileron Therapeutics Inc.

Quick analysis of Aileron Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Aileron Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.29
Expected worth in 1 year
$-0.06
How sure are you?
21.9%

+ What do you gain per year?

Total Gains per Share
$-2.35
Return On Investment
-43.5%

For what price can you sell your share?

Current Price per Share
$5.41
Expected price per share
$2.5399 - $6.42
How sure are you?
50%

1. Valuation of Aileron Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$5.41

Intrinsic Value Per Share

$0.16 - $2.08

Total Value Per Share

$2.45 - $4.37

2. Growth of Aileron Therapeutics Inc (5 min.)




Is Aileron Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$11.1m$32.8m-$18.6m-130.9%

How much money is Aileron Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$3.1m-$7.3m$4.2m134.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Aileron Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#673 / 1037

Most Revenue
#931 / 1037

Most Profit
#385 / 1037

Most Efficient
#375 / 1037

What can you expect buying and holding a share of Aileron Therapeutics Inc? (5 min.)

Welcome investor! Aileron Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Aileron Therapeutics Inc.

What can you expect buying and holding a share of Aileron Therapeutics Inc?

First you should know what it really means to hold a share of Aileron Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Aileron Therapeutics Inc is $5.41. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aileron Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aileron Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.29. Based on the TTM, the Book Value Change Per Share is $-0.59 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aileron Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.37-6.9%-0.51-9.4%-1.51-28.0%-1.19-22.0%-1.33-24.5%
Usd Book Value Change Per Share-0.33-6.0%-0.59-10.9%-1.40-25.9%-0.15-2.8%0.071.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.33-6.0%-0.59-10.9%-1.40-25.9%-0.15-2.8%0.071.3%
Usd Price Per Share1.52-1.73-0.39-1.04-2.25-
Price to Earnings Ratio-1.02--0.93--0.06--0.32--0.52-
Price-to-Total Gains Ratio-4.65--3.70--0.28--1.93--1.63-
Price to Book Ratio0.66-0.60-0.06-0.29-0.37-
Price-to-Total Gains Ratio-4.65--3.70--0.28--1.93--1.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.41
Number of shares184
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.59-0.15
Usd Total Gains Per Share-0.59-0.15
Gains per Quarter (184 shares)-108.26-27.93
Gains per Year (184 shares)-433.04-111.73
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-433-4430-112-122
20-866-8760-223-234
30-1299-13090-335-346
40-1732-17420-447-458
50-2165-21750-559-570
60-2598-26080-670-682
70-3031-30410-782-794
80-3464-34740-894-906
90-3897-39070-1006-1018
100-4330-43400-1117-1130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.032.00.00.0%0.032.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%7.022.03.021.9%7.022.03.021.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.032.00.0%0.00.032.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%7.022.03.021.9%7.022.03.021.9%

Fundamentals of Aileron Therapeutics Inc

About Aileron Therapeutics Inc

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-02-27 16:42:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Aileron Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Aileron Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aileron Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--172.8%+172.8%
TTM--206.5%+206.5%
YOY--251.7%+251.7%
5Y--465.8%+465.8%
10Y--595.4%+595.4%
1.1.2. Return on Assets

Shows how efficient Aileron Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • -14.2% Return on Assets means that Aileron Therapeutics Inc generated $-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aileron Therapeutics Inc:

  • The MRQ is -14.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -18.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.2%TTM-18.4%+4.1%
TTM-18.4%YOY-20.4%+2.0%
TTM-18.4%5Y-20.7%+2.3%
5Y-20.7%10Y-31.8%+11.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.2%-12.4%-1.8%
TTM-18.4%-12.2%-6.2%
YOY-20.4%-11.1%-9.3%
5Y-20.7%-13.6%-7.1%
10Y-31.8%-15.1%-16.7%
1.1.3. Return on Equity

Shows how efficient Aileron Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • -16.3% Return on Equity means Aileron Therapeutics Inc generated $-0.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aileron Therapeutics Inc:

  • The MRQ is -16.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -21.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.3%TTM-21.4%+5.1%
TTM-21.4%YOY-23.5%+2.1%
TTM-21.4%5Y-29.3%+7.9%
5Y-29.3%10Y-47.1%+17.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.3%-15.8%-0.5%
TTM-21.4%-15.8%-5.6%
YOY-23.5%-14.1%-9.4%
5Y-29.3%-18.3%-11.0%
10Y-47.1%-19.4%-27.7%

1.2. Operating Efficiency of Aileron Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Aileron Therapeutics Inc is operating .

  • Measures how much profit Aileron Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aileron Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--314.9%+314.9%
TTM--211.1%+211.1%
YOY--276.2%+276.2%
5Y--459.9%+459.9%
10Y--596.5%+596.5%
1.2.2. Operating Ratio

Measures how efficient Aileron Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aileron Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.876-2.876
TTM-3.223-3.223
YOY-3.547-3.547
5Y-5.795-5.795
10Y-7.396-7.396

1.3. Liquidity of Aileron Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Aileron Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.88 means the company has $7.88 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aileron Therapeutics Inc:

  • The MRQ is 7.877. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.982. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.877TTM7.982-0.105
TTM7.982YOY8.203-0.221
TTM7.9825Y7.288+0.694
5Y7.28810Y6.347+0.940
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.8773.992+3.885
TTM7.9824.478+3.504
YOY8.2035.562+2.641
5Y7.2886.255+1.033
10Y6.3476.509-0.162
1.3.2. Quick Ratio

Measures if Aileron Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 7.43 means the company can pay off $7.43 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aileron Therapeutics Inc:

  • The MRQ is 7.432. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.795. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.432TTM9.795-2.364
TTM9.795YOY14.352-4.557
TTM9.7955Y11.227-1.432
5Y11.22710Y9.772+1.455
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.4323.662+3.770
TTM9.7954.184+5.611
YOY14.3525.484+8.868
5Y11.2276.041+5.186
10Y9.7726.333+3.439

1.4. Solvency of Aileron Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Aileron Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aileron Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.13 means that Aileron Therapeutics Inc assets are financed with 12.7% credit (debt) and the remaining percentage (100% - 12.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aileron Therapeutics Inc:

  • The MRQ is 0.127. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.134. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.127TTM0.134-0.007
TTM0.134YOY0.129+0.004
TTM0.1345Y0.230-0.096
5Y0.23010Y0.700-0.470
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1270.331-0.204
TTM0.1340.325-0.191
YOY0.1290.264-0.135
5Y0.2300.371-0.141
10Y0.7000.380+0.320
1.4.2. Debt to Equity Ratio

Measures if Aileron Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 14.5% means that company has $0.15 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aileron Therapeutics Inc:

  • The MRQ is 0.145. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.156. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.145TTM0.156-0.011
TTM0.156YOY0.150+0.006
TTM0.1565Y0.350-0.194
5Y0.35010Y0.354-0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1450.371-0.226
TTM0.1560.396-0.240
YOY0.1500.332-0.182
5Y0.3500.428-0.078
10Y0.3540.479-0.125

2. Market Valuation of Aileron Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aileron Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Aileron Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -1.02 means the investor is paying $-1.02 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aileron Therapeutics Inc:

  • The EOD is -3.617. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.016. Based on the earnings, the company is expensive. -2
  • The TTM is -0.931. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.617MRQ-1.016-2.601
MRQ-1.016TTM-0.931-0.085
TTM-0.931YOY-0.064-0.867
TTM-0.9315Y-0.322-0.609
5Y-0.32210Y-0.515+0.193
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.617-2.699-0.918
MRQ-1.016-2.251+1.235
TTM-0.931-2.823+1.892
YOY-0.064-4.293+4.229
5Y-0.322-6.216+5.894
10Y-0.515-6.249+5.734
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aileron Therapeutics Inc:

  • The EOD is -4.029. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.132. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.704. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.029MRQ-1.132-2.897
MRQ-1.132TTM-0.704-0.428
TTM-0.704YOY-0.071-0.633
TTM-0.7045Y-0.284-0.419
5Y-0.28410Y-0.692+0.408
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.029-3.506-0.523
MRQ-1.132-2.833+1.701
TTM-0.704-3.461+2.757
YOY-0.071-5.896+5.825
5Y-0.284-8.460+8.176
10Y-0.692-8.868+8.176
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Aileron Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.66 means the investor is paying $0.66 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aileron Therapeutics Inc:

  • The EOD is 2.360. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.663. Based on the equity, the company is cheap. +2
  • The TTM is 0.598. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.360MRQ0.663+1.697
MRQ0.663TTM0.598+0.065
TTM0.598YOY0.055+0.543
TTM0.5985Y0.288+0.310
5Y0.28810Y0.372-0.085
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.3602.111+0.249
MRQ0.6631.879-1.216
TTM0.5982.119-1.521
YOY0.0552.970-2.915
5Y0.2883.686-3.398
10Y0.3724.058-3.686
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aileron Therapeutics Inc.

3.1. Institutions holding Aileron Therapeutics Inc

Institutions are holding 26.182% of the shares of Aileron Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31SATTER MANAGEMENT CO., L.P.16.99853.368883046600
2023-09-30Geode Capital Management, LLC1.156705651314672.665
2023-09-30Vanguard Group Inc0.8174039934-539-1.3318
2023-12-31Gagnon Securities LLC0.77670.027837947379470
2023-12-31Blair William & Co0.57920.000328297-700-2.414
2023-12-31Renaissance Technologies Corp0.57350.000128019905547.7484
2023-09-30KCK Ltd0.45730.04822234100
2023-09-30Susquehanna International Group, LLP0.4125020155201550
2023-09-30HighTower Advisors, LLC0.39310.00011920400
2023-09-30Tower Research Capital LLC0.09230.0002450976720.4971
2023-09-30Jfs Wealth Advisors, LLC0.03250.0002159000
2023-09-30Morgan Stanley - Brokerage Accounts0.02560125000
2023-12-31U.S. Bancorp0.02560125000
2023-09-30BlackRock Inc0.0039018900
2023-09-30Bank of America Corp0.0026012500
2023-09-30Wells Fargo & Co0.000502400
2023-09-30Acadian Asset Management LLC0.0003017170
2023-09-30ICA Group Wealth Management, LLC000-100-100
2023-09-30UBS Group AG000-1357-100
Total 22.34823.44571091830+66712+6.1%

3.2. Funds holding Aileron Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr0.82520.00024031400
2024-01-31Fidelity Nasdaq Composite ETF0.81590.00323985900
2023-12-31Vifag 2002 SICAV0.51170.13042500000
2023-12-31Fidelity Extended Market Index0.35670.000217427-44-0.2518
2023-12-31Fidelity Nasdaq Composite Index0.08270.0001403900
2023-12-31Fidelity Series Total Market Index0.07130348100
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06780.0002331400
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05450.0002266250.1882
2023-12-31Fidelity Total Market Index0.04920240500
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04410.0001215300
2023-12-31Northern Trust Extended Eq Market Idx0.04410.0001215300
2023-12-31Spartan Total Market Index Pool E0.03190155800
2023-12-31SSgA U.S. Extended Market Index Class I0.02950.0002144000
2024-01-31State St US Extended Mkt Indx NL Cl C0.02950.0003144000
2023-12-31SSgA U.S. Total Market Index Strategy0.00850415-10-2.3529
2024-01-31State St US Ttl Mkt Indx SL Cl I0.0082040000
2023-12-31NT US Market Cap Idx Fd - L0.0039019100
2023-12-31Northern Trust Wilshire 50000.0039019100
2023-09-30BlackRock Extended Mkt Composite0.0039018900
2023-12-31BlackRock Extended Equity Market K0.0034016500
Total 3.04590.1352148796-490.0%

3.3. Insider Transactions

Insiders are holding 0.662% of the shares of Aileron Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-15James Brian WindsorBUY2253.37
2023-11-20James Brian WindsorBUY50761.97

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Aileron Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.327-0.588+80%-1.403+329%-0.152-54%0.072-556%
Book Value Per Share--2.2922.911-21%6.720-66%5.201-56%3.070-25%
Current Ratio--7.8777.982-1%8.203-4%7.288+8%6.347+24%
Debt To Asset Ratio--0.1270.134-5%0.129-2%0.230-45%0.700-82%
Debt To Equity Ratio--0.1450.156-7%0.150-3%0.350-59%0.354-59%
Dividend Per Share----0%-0%-0%-0%
Eps---0.374-0.509+36%-1.514+305%-1.192+219%-1.326+255%
Free Cash Flow Per Share---0.336-0.708+111%-1.367+307%-1.166+247%-1.152+243%
Free Cash Flow To Equity Per Share---0.342-0.709+107%-1.367+299%-0.176-48%-0.007-98%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--2.080--------
Intrinsic Value_10Y_min--0.160--------
Intrinsic Value_1Y_max---3.644--------
Intrinsic Value_1Y_min---3.582--------
Intrinsic Value_3Y_max---8.013--------
Intrinsic Value_3Y_min---7.709--------
Intrinsic Value_5Y_max---8.842--------
Intrinsic Value_5Y_min---8.460--------
Market Cap26430609.100+72%7425975.2008451932.300-12%1883364.105+294%5070450.981+46%14255084.309-48%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio2.360+72%0.6630.598+11%0.055+1101%0.288+130%0.372+78%
Pe Ratio-3.617-256%-1.016-0.931-8%-0.064-94%-0.322-68%-0.515-49%
Price Per Share5.410+72%1.5201.730-12%0.386+294%1.038+46%2.254-33%
Price To Free Cash Flow Ratio-4.029-256%-1.132-0.704-38%-0.071-94%-0.284-75%-0.692-39%
Price To Total Gains Ratio-16.561-256%-4.653-3.700-20%-0.276-94%-1.927-59%-1.632-65%
Quick Ratio--7.4329.795-24%14.352-48%11.227-34%9.772-24%
Return On Assets---0.142-0.184+29%-0.204+43%-0.207+45%-0.318+123%
Return On Equity---0.163-0.214+31%-0.235+44%-0.293+80%-0.471+188%
Total Gains Per Share---0.327-0.588+80%-1.403+329%-0.152-54%0.072-556%
Usd Book Value--11198000.00014222000.000-21%32832000.000-66%25410600.000-56%15995687.500-30%
Usd Book Value Change Per Share---0.327-0.588+80%-1.403+329%-0.152-54%0.072-556%
Usd Book Value Per Share--2.2922.911-21%6.720-66%5.201-56%3.070-25%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.374-0.509+36%-1.514+305%-1.192+219%-1.326+255%
Usd Free Cash Flow---1640000.000-3456500.000+111%-6677750.000+307%-5694703.297+247%-5753408.311+251%
Usd Free Cash Flow Per Share---0.336-0.708+111%-1.367+307%-1.166+247%-1.152+243%
Usd Free Cash Flow To Equity Per Share---0.342-0.709+107%-1.367+299%-0.176-48%-0.007-98%
Usd Market Cap26430609.100+72%7425975.2008451932.300-12%1883364.105+294%5070450.981+46%14255084.309-48%
Usd Price Per Share5.410+72%1.5201.730-12%0.386+294%1.038+46%2.254-33%
Usd Profit---1827000.000-3138000.000+72%-7354750.000+303%-5944800.000+225%-6134093.750+236%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.327-0.588+80%-1.403+329%-0.152-54%0.072-556%
 EOD+5 -3MRQTTM+19 -10YOY+21 -85Y+16 -1310Y+14 -15

4.2. Fundamental Score

Let's check the fundamental score of Aileron Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.617
Price to Book Ratio (EOD)Between0-12.360
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than17.432
Current Ratio (MRQ)Greater than17.877
Debt to Asset Ratio (MRQ)Less than10.127
Debt to Equity Ratio (MRQ)Less than10.145
Return on Equity (MRQ)Greater than0.15-0.163
Return on Assets (MRQ)Greater than0.05-0.142
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Aileron Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.519
Ma 20Greater thanMa 505.170
Ma 50Greater thanMa 1004.690
Ma 100Greater thanMa 2003.453
OpenGreater thanClose5.550
Total5/5 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Total Other Income Expense Net 1144215676232-51181-186-5



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets12,822
Total Liabilities1,624
Total Stockholder Equity11,198
 As reported
Total Liabilities 1,624
Total Stockholder Equity+ 11,198
Total Assets = 12,822

Assets

Total Assets12,822
Total Current Assets12,793
Long-term Assets29
Total Current Assets
Cash And Cash Equivalents 12,069
Other Current Assets 699
Total Current Assets  (as reported)12,793
Total Current Assets  (calculated)12,768
+/- 25
Long-term Assets
Property Plant Equipment 29
Long-term Assets  (as reported)29
Long-term Assets  (calculated)29
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,624
Long-term Liabilities0
Total Stockholder Equity11,198
Total Current Liabilities
Accounts payable 484
Other Current Liabilities 1,140
Total Current Liabilities  (as reported)1,624
Total Current Liabilities  (calculated)1,624
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock91
Retained Earnings -281,178
Other Stockholders Equity 292,285
Total Stockholder Equity (as reported)11,198
Total Stockholder Equity (calculated)11,198
+/-0
Other
Capital Stock91
Cash and Short Term Investments 12,069
Common Stock Shares Outstanding 4,541
Liabilities and Stockholders Equity 12,822
Net Debt -12,069
Net Invested Capital 11,198
Net Tangible Assets 11,198
Net Working Capital 11,169
Property Plant and Equipment Gross 324



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
> Total Assets 
5,940
0
0
0
22,021
17,155
15,105
59,036
52,688
52,688
42,577
38,133
30,312
22,399
40,193
33,952
26,473
20,373
26,125
22,239
16,341
64,671
60,531
54,768
48,481
40,255
33,770
27,232
22,007
17,157
13,991
12,822
12,82213,99117,15722,00727,23233,77040,25548,48154,76860,53164,67116,34122,23926,12520,37326,47333,95240,19322,39930,31238,13342,57752,68852,68859,03615,10517,15522,0210005,940
   > Total Current Assets 
4,026
0
0
0
21,073
15,982
11,992
58,117
51,840
51,840
37,206
30,053
21,775
14,389
32,559
26,497
19,550
13,687
19,670
15,974
16,326
64,324
60,152
54,423
48,177
39,993
33,550
27,054
21,873
17,105
13,952
12,793
12,79313,95217,10521,87327,05433,55039,99348,17754,42360,15264,32416,32615,97419,67013,68719,55026,49732,55914,38921,77530,05337,20651,84051,84058,11711,99215,98221,0730004,026
       Cash And Cash Equivalents 
3,768
0
0
0
20,715
8,029
9,397
13,428
11,863
11,863
11,980
7,716
10,635
11,272
10,157
6,867
5,311
10,697
17,124
7,850
7,046
19,283
10,748
7,603
3,600
7,449
7,628
4,839
5,194
7,783
13,167
12,069
12,06913,1677,7835,1944,8397,6287,4493,6007,60310,74819,2837,0467,85017,12410,6975,3116,86710,15711,27210,6357,71611,98011,86311,86313,4289,3978,02920,7150003,768
       Short-term Investments 
0
0
0
0
25
7,265
1,946
43,437
38,889
38,889
23,811
20,229
10,060
1,998
21,365
17,694
12,967
1,998
1,756
6,271
6,759
44,068
48,731
44,629
42,333
30,626
24,754
20,638
16,048
8,938
499
0
04998,93816,04820,63824,75430,62642,33344,62948,73144,0686,7596,2711,7561,99812,96717,69421,3651,99810,06020,22923,81138,88938,88943,4371,9467,265250000
       Other Current Assets 
258
0
0
0
358
688
649
1,252
1,088
1,088
1,415
2,108
1,055
1,119
1,012
1,911
1,247
967
765
1,828
1,928
948
648
2,166
2,219
1,893
1,143
1,552
606
359
261
699
6992613596061,5521,1431,8932,2192,1666489481,9281,8287659671,2471,9111,0121,1191,0552,1081,4151,0881,0881,252649688358000258
   > Long-term Assets 
0
0
0
0
948
1,173
3,113
919
848
848
5,371
8,080
8,537
8,010
7,634
7,455
6,923
6,686
6,455
6,265
15
347
379
345
304
262
220
178
134
52
39
29
293952134178220262304345379347156,2656,4556,6866,9237,4557,6348,0108,5378,0805,3718488489193,1131,1739480000
       Property Plant Equipment 
351
0
0
0
107
123
109
111
154
154
4,123
6,832
7,290
6,941
6,764
6,585
6,355
6,118
5,887
5,697
15
326
355
321
280
238
196
154
110
52
39
29
293952110154196238280321355326155,6975,8876,1186,3556,5856,7646,9417,2906,8324,123154154111109123107000351
       Long-term Assets Other 
0
0
0
0
841
1,050
3,004
808
694
694
1,248
1,248
1,247
1,069
870
870
568
568
568
568
0
21
24
24
24
24
24
24
24
0
0
0
000242424242424242105685685685688708701,0691,2471,2481,2486946948083,0041,0508410000
> Total Liabilities 
2,578
0
0
0
133,827
2,875
135,883
5,023
4,891
4,891
9,709
12,102
10,712
9,552
10,209
11,136
10,425
10,604
9,471
9,781
4,179
3,252
4,401
4,659
4,577
4,146
5,151
4,536
3,384
2,884
1,197
1,624
1,6241,1972,8843,3844,5365,1514,1464,5774,6594,4013,2524,1799,7819,47110,60410,42511,13610,2099,55210,71212,1029,7094,8914,8915,023135,8832,875133,8270002,578
   > Total Current Liabilities 
2,549
0
0
0
4,071
2,871
5,471
5,023
4,891
4,891
6,364
7,105
5,370
4,623
5,387
6,428
5,839
6,143
4,926
5,249
3,960
3,073
4,273
4,560
4,508
4,146
5,151
4,536
3,384
2,884
1,197
1,624
1,6241,1972,8843,3844,5365,1514,1464,5084,5604,2733,0733,9605,2494,9266,1435,8396,4285,3874,6235,3707,1056,3644,8914,8915,0235,4712,8714,0710002,549
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
1,020
0
0
387
406
426
446
468
661
560
168
422
93
93
93
131
100
67
33
0
0
0
0003367100131939393422168560661468446426406387001,0200000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
1,020
0
0
387
0
0
0
0
171
48
168
329
0
0
0
0
0
0
0
0
0
0
0000000000329168481710000387001,0200000000000
       Accounts payable 
641
0
0
0
1,971
1,035
2,212
1,650
4,891
1,600
1,583
2,994
1,731
858
1,719
2,349
1,452
1,088
993
1,002
1,596
560
1,016
1,035
1,210
1,023
1,741
945
1,720
458
136
484
4841364581,7209451,7411,0231,2101,0351,0165601,5961,0029931,0881,4522,3491,7198581,7312,9941,5831,6004,8911,6502,2121,0351,971000641
       Other Current Liabilities 
1,908
0
0
0
2,100
1,836
3,259
3,373
3,291
3,291
4,781
4,111
3,639
289
362
343
352
281
227
279
2,196
2,091
3,164
3,432
3,205
2,992
3,310
3,524
1,631
2,426
1,061
1,140
1,1401,0612,4261,6313,5243,3102,9923,2053,4323,1642,0912,1962792272813523433622893,6394,1114,7813,2913,2913,3733,2591,8362,1000001,908
   > Long-term Liabilities 
0
0
0
0
129,756
4
130,412
0
0
0
3,345
4,997
5,342
4,929
4,822
4,708
4,586
4,461
4,545
4,532
219
179
128
99
69
1,154
1,841
1,012
1,753
458
0
0
004581,7531,0121,8411,15469991281792194,5324,5454,4614,5864,7084,8224,9295,3424,9973,345000130,4124129,7560000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
3,345
4,997
5,342
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000005,3424,9973,3450000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
-1,020
0
0
4,929
4,822
4,708
4,586
4,461
4,161
4,148
-168
-205
128
99
69
0
0
0
0
0
0
0
00000006999128-205-1684,1484,1614,4614,5864,7084,8224,92900-1,0200000000000
       Warrants
0
0
0
0
0
0
130,412
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000130,412000000
       Other Liabilities 
29
0
0
0
11
4
0
0
0
0
3,345
4,997
5,342
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,536
0
0
0
0
00004,536000000000000005,3424,9973,345000041100029
> Total Stockholder Equity
3,362
0
0
0
-111,806
14,280
-120,778
54,013
47,797
47,797
32,868
26,031
19,600
12,847
29,984
22,816
16,048
9,769
16,654
12,458
12,162
61,419
56,130
50,109
43,904
36,109
28,619
22,696
18,623
14,273
12,794
11,198
11,19812,79414,27318,62322,69628,61936,10943,90450,10956,13061,41912,16212,45816,6549,76916,04822,81629,98412,84719,60026,03132,86847,79747,79754,013-120,77814,280-111,8060003,362
   Common Stock
4
0
0
0
0
11
0
15
15
15
15
15
15
15
28
28
28
28
39
40
44
90
90
91
91
91
91
91
91
91
91
91
9191919191919191919090444039282828281515151515151501100004
   Retained Earnings Total Equity0000-268,2380000-231,953-226,267-219,292-214,296-209,273-204,883-198,135-190,900-183,151-175,979-168,493-161,459-154,025-144,534-136,946-130,081-123,822000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-2,094
-2,116
0
-6
-1,979
-33
-12
-3
-5
-1,206
24
17
7
-1
-2
-1
-2
-7
6
1
-13
-75
-101
-98
-48
-10
-2
0
0-2-10-48-98-101-75-1316-7-2-1-2-171724-1,206-5-3-12-33-1,979-60-2,116-2,0940000
   Capital Surplus 
0
0
0
0
0
0
3,044
184,085
184,761
185,544
186,890
187,478
188,083
188,811
213,083
213,671
214,148
214,625
225,890
226,715
231,412
287,603
287,987
0
0
0
0
290,941
0
0
0
0
0000290,9410000287,987287,603231,412226,715225,890214,625214,148213,671213,083188,811188,083187,478186,890185,544184,761184,0853,044000000
   Treasury Stock00000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
4,630
135,284
-127,368
125,049
-33
184,761
186,890
187,478
188,083
188,811
213,083
213,671
214,148
214,625
225,890
226,715
231,412
287,603
287,987
288,674
289,282
289,971
290,499
290,941
291,365
291,756
292,056
292,285
292,285292,056291,756291,365290,941290,499289,971289,282288,674287,987287,603231,412226,715225,890214,625214,148213,671213,083188,811188,083187,478186,890184,761-33125,049-127,368135,2844,6300000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-12,749
Operating Income-12,749-12,749
 
Operating Expense (+$)
Research Development4,421
Selling General Administrative8,328
Selling And Marketing Expenses-
Operating Expense12,74912,749
 
Net Interest Income (+$)
Interest Income442
Interest Expense--
Other Finance Cost-0
Net Interest Income442
 
Pretax Income (+$)
Operating Income-12,749
Net Interest Income442
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-12,940-12,116
EBIT - interestExpense = 0
-12,940
-12,940
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--12,940
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-12,940
Tax Provision--
Net Income From Continuing Ops-12,940-12,940
Net Income-12,940
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-633-442
 

Technical Analysis of Aileron Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aileron Therapeutics Inc. The general trend of Aileron Therapeutics Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aileron Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aileron Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.12 < 6.4 < 6.42.

The bearish price targets are: 4.2485 > 3.93 > 2.5399.

Tweet this
Aileron Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aileron Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aileron Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aileron Therapeutics Inc. The current macd is 0.28041785.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aileron Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Aileron Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Aileron Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aileron Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAileron Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aileron Therapeutics Inc. The current adx is 38.99.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Aileron Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Aileron Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aileron Therapeutics Inc. The current sar is 4.76188355.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Aileron Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aileron Therapeutics Inc. The current rsi is 56.52. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Aileron Therapeutics Inc Daily Relative Strength Index (RSI) ChartAileron Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aileron Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aileron Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Aileron Therapeutics Inc Daily Stochastic Oscillator ChartAileron Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aileron Therapeutics Inc. The current cci is 52.74.

Aileron Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAileron Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aileron Therapeutics Inc. The current cmo is 8.59589711.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Aileron Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAileron Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aileron Therapeutics Inc. The current willr is -43.1372549.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Aileron Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Aileron Therapeutics Inc Daily Williams %R ChartAileron Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aileron Therapeutics Inc.

Aileron Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aileron Therapeutics Inc. The current atr is 0.39889603.

Aileron Therapeutics Inc Daily Average True Range (ATR) ChartAileron Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aileron Therapeutics Inc. The current obv is 3,407,128.

Aileron Therapeutics Inc Daily On-Balance Volume (OBV) ChartAileron Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aileron Therapeutics Inc. The current mfi is 64.68.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Aileron Therapeutics Inc Daily Money Flow Index (MFI) ChartAileron Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aileron Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-25STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-10-30RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-10ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-17BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Aileron Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aileron Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.519
Ma 20Greater thanMa 505.170
Ma 50Greater thanMa 1004.690
Ma 100Greater thanMa 2003.453
OpenGreater thanClose5.550
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Aileron Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Aileron Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aileron Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aileron Therapeutics Inc

I send you an email if I find something interesting about Aileron Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aileron Therapeutics Inc.

Receive notifications about Aileron Therapeutics Inc in your mailbox!